Company profile for ImCheck Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ImCheck Therapeutics is driving innovation in two powerful new areas of immune system modulation: the butyrophilins superfamily of immunomodulatory molecules and gamma-delta T cells. The company is developing next generation immunotherapeutics for patients with severe unmet medical needs with a primary focus on immuno-oncology. Our growing understanding of these novel targets has also identified unique opportunities in immun...
ImCheck Therapeutics is driving innovation in two powerful new areas of immune system modulation: the butyrophilins superfamily of immunomodulatory molecules and gamma-delta T cells. The company is developing next generation immunotherapeutics for patients with severe unmet medical needs with a primary focus on immuno-oncology. Our growing understanding of these novel targets has also identified unique opportunities in immune-mediated inflammatory disease also known as autoimmune diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
31 chemin Joseph Aiguier CS 70071 13402, MARSEILLE Cedex 09
Telephone
Telephone
+33 4 13 96 14 90
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/07/3201152/0/en/ImCheck-Reports-Durable-Responses-and-Early-Overall-Survival-Signal-with-ICT01-in-First-line-AML-at-ASH-2025.html

GLOBENEWSWIRE
07 Dec 2025

https://www.globenewswire.com/news-release/2025/12/05/3200499/0/en/ImCheck-Announces-Oral-Presentation-of-ICT01-First-Line-AML-Data-at-the-67th-ASH-Annual-Meeting.html

GLOBENEWSWIRE
05 Dec 2025

https://www.biospace.com/business/ipsen-puts-up-1-6b-to-absorb-imcheck-for-mid-stage-leukemia-antibody

BIOSPACE
24 Oct 2025

https://www.globenewswire.com/news-release/2025/07/21/3118620/0/en/ImCheck-s-Announces-EMA-Orphan-Drug-Designation-for-ICT01-as-Treatment-for-Acute-Myeloid-Leukemia.html

GLOBENEWSWIRE
21 Jul 2025

https://www.globenewswire.com/news-release/2025/07/18/3117771/0/en/ImCheck-s-ICT01-Receives-FDA-Orphan-Drug-Designation-for-Treatment-of-Acute-Myeloid-Leukemia.html

GLOBENEWSWIRE
18 Jul 2025

https://www.globenewswire.com/news-release/2025/05/22/3087173/0/en/ImCheck-Reports-High-Remission-Rates-in-AML-Patients-with-ICT01-Combination-Therapy-at-ASCO-2025.html

GLOBENEWSWIRE
22 May 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty